Immunotherapy (checkpoint inhibitors, CAR‑T cells, cytokines like IL‑15 agonists, cancer vaccines) has shown that the immune system can eliminate even advanced cancers in some patients. But responses are highly variable:

• Only a subset of patients respond.
• Many develop resistance.
• Toxic immune‑related side effects can be severe.
• Choosing the right combination and dose is complex.

Advanced artificial intelligence (AI) is now being used to:

1. Design better immune‑based therapies (vaccines, CAR‑T/NK, antibody constructs).
2. Personalize them to each patient’s tumor and immune system.
3. Predict and monitor responses and toxicities.
4. Optimize combinations with chemo, radiation, targeted drugs.

In short, AI is shifting cancer immunotherapy from empirical trial‑and‑error toward a data‑driven, model‑guided engineering discipline.

2.1 AI‑Designed Personalized Cancer Vaccines

Goal: Train a patient’s T cells to recognize and attack their own tumor using vaccines that encode neoantigens—mutated peptides present on cancer cells but not on normal tissues.

What AI does:

1. Tumor sequencing and mutation calling
   • Next‑generation sequencing (NGS) identifies somatic mutations in a patient’s tumor and matched normal tissue.
2. Neoantigen prediction
   AI models analyze:
   • Which mutations create altered peptides.
   • Which of these will bind strongly to the patient’s specific HLA (MHC) molecules.
   • Which are likely to be processed and actually presented on tumor cell surfaces.
   • Which peptides are immunogenic (can trigger strong CD8+ and CD4+ T‑cell responses).
3. Vaccine design
   • Selected top neoantigens are encoded into an mRNA, DNA, peptide mix, or biomaterial‑based vaccine platform.
   • AI helps rank and combine up to ~20–34 neoantigens per vaccine to maximize breadth and potency.

Evidence and recent advances:

• A 2025–2026 wave of clinical studies shows personalized mRNA cancer vaccines combined with checkpoint inhibitors (e.g., KEYNOTE‑942 in melanoma) substantially reduce recurrence risk and boost neoantigen‑specific T‑cell responses compared to checkpoint inhibitors alone [1][2].
• Reviews on RNA‑based cancer vaccines highlight that individualized neoantigen mRNA vaccines can encode dozens of patient‑specific targets, with early trials reporting notable reductions in recurrence when combined with PD‑1 blockade [1][2].
• A 2026 Nature paper describes individualized neoantigen RNA vaccines using NGS plus AI prediction to select T‑cell targets, inducing durable T‑cell immunity in treated patients [3].
• A first‑in‑human trial of a personalized biomaterial‑based cancer vaccine (Harvard Wyss Institute) showed feasibility, safety, and immune activation, and is now moving toward combinations with checkpoint blockade [4].

How this “boosts” the immune system against cancer:

• Increases tumor‑specific T‑cell clones that can recognize tiny remnants of disease.
• Converts “immune‑cold” tumors into “hot” ones more responsive to checkpoint inhibitors.
• Provides immune memory, helping prevent relapse.

Actionable implications:

• For high‑risk or relapsed solid tumors (melanoma, certain lung, pancreatic, and colorectal cancers), AI‑designed neoantigen vaccines combined with checkpoint blockade are rapidly becoming a central research and early clinical strategy.

---

2.2 AI‑Guided Engineering of CAR‑T and CAR‑NK Cells

Goal: Genetically engineer a patient’s immune cells (T or NK cells) to express synthetic receptors (CARs) that target cancer cells with high specificity and potency.

Where AI helps:

1. Optimizing CAR design
   AI models analyze large datasets of CAR configurations and outcomes to:
   • Predict which antigen‑binding domains (scFvs) bind tumor antigens strongly without cross‑reacting with healthy tissue.
   • Tune signaling domains to balance activation, persistence, and safety (reducing exhaustion, CRS, neurotoxicity).
   • Identify sequence motifs linked to superior proliferation and survival.
2. Selecting targets and combinations
   • AI integrates tumor genomics and proteomics to find ideal target antigens (e.g., CD19, BCMA, EGFRvIII) and combinations (dual CARs) to reduce antigen escape.
   • Recent work describes AI‑guided CAR designs and pathway modulation strategies to enhance long‑term efficacy of CD19 CAR‑T cells [5].
3. In vivo and ex vivo engineering strategies
   • Emerging in vivo CAR‑T approaches use viral or non‑viral vectors to reprogram T cells directly in the patient’s body. AI helps select integration sites, vector doses, and control circuits to maximize safety and efficiency [6][7].
   • AI‑assisted CRISPR editing identifies optimal genomic loci for CAR insertion to avoid insertional mutagenesis and preserve native T‑cell function.

Recent developments:

• Reviews in 2025–2026 describe how AI is intersecting with CAR‑T development—guiding CAR construction, improving manufacturing, and predicting efficacy and safety [5][8].
• 2026 reports on in vivo site‑specific CAR engineering in patients highlight CRISPR‑based insertion of CAR constructs into specific T‑cell loci, reducing manufacturing time and potentially broadening access [7].
• Preclinical and early clinical data on next‑generation CAR‑T for solid tumors show designs that secrete IL‑12 or block PD‑L1 locally within the tumor microenvironment; these designs are informed by AI analysis of TME features [9].

How this boosts anti‑cancer immunity:

• Dramatically expands high‑affinity tumor‑specific effector cells.
• Overcomes some natural tolerance and exhaustion mechanisms that blunt endogenous responses.
• Potentially extends CAR‑based therapies from blood cancers into solid tumors by optimizing trafficking, persistence, and on‑target effects in the TME.

Actionable implications:

• For refractory hematologic malignancies and experimental solid tumor applications, AI‑assisted CAR‑T/NK design is a fast‑moving area that can improve both response rates and safety compared to earlier CAR generations.

---

2.3 AI‑Driven Optimization of Chemo‑Immunotherapy and Radio‑Immunotherapy

Goal: Use AI to find synergistic schedules and combinations of chemotherapy, radiotherapy, and immunotherapy that maximize immune activation and tumor death while minimizing systemic toxicity.

Key functions:

1. Modeling immunogenic cell death (ICD)
   • Certain chemotherapies and radiation exposures cause tumor cells to die in a way that releases danger signals and antigens, effectively acting as an in situ vaccine.
   • AI models integrate multi‑omics and clinical data to predict which regimens produce the strongest ICD and how they reshape “cold” tumors into “hot,” T‑cell–inflamed tumors [10].
2. Personalizing combination regimens
   • AI systems evaluate patient‑specific tumor genomics, TME signatures, and lab parameters to:
     • Predict benefit from chemo‑immunotherapy vs. immunotherapy alone.
     • Choose optimal drugs, doses, and timing (e.g., when to give checkpoint inhibitors relative to radiation fractions).
3. Adaptive adjustment
   • Longitudinal data (labs, imaging, symptoms) feed ML models that dynamically adjust regimens—escalating or de‑escalating immune stimulation based on early response or toxicity.

Evidence:

• A 2026 review on AI‑enhanced synergistic chemo‑immunotherapy emphasizes:
  • AI can identify optimal chemo‑immunotherapy combinations by integrating multi‑omics and TME features.
  • Chemo can remodel tumors into more immunogenic states, enhancing checkpoint inhibitor efficacy when optimally scheduled [10].
• A parallel review on AI‑driven immunotherapy and radiotherapy combinations describes AI‑based predictive biomarkers and treatment planners that align radiation dose and field design with expected immune activation [11].

How this boosts immunity:

• CD8+ and NK cells gain more and better antigens from ICD.
• AI‑optimized sequencing avoids deep lymphopenia that would otherwise cripple immune‑based strategies.
• More patients convert from non‑responders to responders by reconditioning the tumor microenvironment.

---

2.4 AI‑Enhanced Diagnosis, Prognosis, and Immune Monitoring

Goal: Use AI to read signals of immune activity or suppression from complex data (pathology, imaging, blood tests) and guide immunotherapy decisions.

Applications:

1. Pathomics and digital pathology
   • Deep learning models analyze routine H&E slides to quantify:
     • Density and spatial distribution of T cells, B cells, macrophages.
     • Immune‑excluded vs. immune‑inflamed patterns.
   • Recent work presented at AACR 2026 showed a “pathomics” AI platform predicting response to immunotherapy in lung cancer using standard pathology images [12].
2. Radiomics
   • AI extracts features from CT/MRI/PET imaging that correlate with immune infiltration and response to checkpoint blockade [13].
3. Response prediction for checkpoint inhibitors
   • Models trained on large cohorts predict probabilities of benefit from immunotherapy using:
     • PD‑L1 expression.
     • Tumor mutational burden.
     • Gene expression signatures.
     • Clinical and lab data.
   • Reports in 2026 discuss deep learning models that can predict response to immune checkpoint inhibitors in advanced NSCLC, helping select first‑line immunotherapy vs. chemo‑immunotherapy [13].
4. Toxicity and safety monitoring
   • AI can detect patterns in labs, vital signs, and clinical notes that precede immune‑related adverse events (e.g., colitis, myocarditis), enabling earlier intervention.
   • A 2025 review of AI in cancer immunotherapy notes “promising and multifaceted” future trends for AI in safety monitoring [14].

How this boosts effective immunity:

• By putting the right patients on the right immunotherapies, AI ensures that the patients whose immune systems can be effectively mobilized actually receive those treatments.
• Early detection of toxicity allows clinicians to maintain immunotherapy where beneficial, instead of stopping too early or causing severe harm.

---

2.5 AI‑Assisted Discovery of New Immune Targets and Mechanisms

Goal: Use AI as a “co‑scientist” to discover previously unrecognized immune checkpoints, antigens, and regulatory circuits that can be targeted to boost anti‑tumor immunity.

Examples from recent work:

• A 2026 article in Cancer Discovery describes AI “co‑scientists” generating drug candidates, prioritizing immunotherapy targets, and shaping discovery pipelines in pharma and academia [15].
• City of Hope’s 2026 AACR presentations highlight AI‑driven discovery efforts mapping:
  • Why cancers develop earlier in some populations.
  • How tumors develop immune resistance.
  • How AI can reveal new targetable resistance pathways [16].

Specific mechanistic advances:

• Identifying novel glycans and glycan‑binding interactions that tumors use to evade immunity, and exploiting lectins that, when used therapeutically, can “dramatically boost the immune system’s response to cancer cells,” as shown in a 2025 MIT immunotherapy study [17].
• Designing next‑generation antibodies that recruit immune cells more efficiently to tumors; early 2026 research reported “supercharged” antibodies that rally the immune system to hit cancer harder and more effectively [18].

How this boosts immunity:

• Broadens the range of drug targets beyond PD‑1/PD‑L1/CTLA‑4.
• Enables combination strategies that modulate multiple immune pathways simultaneously, tuned to each tumor’s escape mechanisms.

Across all these technologies, AI boosts anti‑cancer immunity by:

1. Increasing the quality of immune targets
   • Better neoantigen selection → more specific and potent T‑cell responses.
   • Safer CAR/TCR targets → strong tumor killing, less off‑tumor toxicity.
2. Enhancing effector cell quantity and fitness
   • CAR‑T/NK, TILs, and vaccines elevate numbers of functional CD8+ T cells and NK cells.
   • AI‑optimized designs reduce exhaustion and improve memory formation.
3. Reprogramming the tumor microenvironment
   • AI guides use of chemo/radiation/cytokines to make tumors less immunosuppressive and more accessible to immune cells.
4. Maintaining balance to avoid harmful autoimmunity
   • Improved prediction and monitoring of immune‑related toxicities helps maintain beneficial anti‑tumor immunity while limiting damage to normal tissues.

Despite the promise, several clinical and systemic challenges remain:

• Data bias and generalizability
  AI models may be trained on limited demographic or disease subsets and may underperform in under‑represented populations.
• Standardization and validation
  Many AI predictors of response/toxicity need robust prospective validation before routine clinical use.
• Cost and infrastructure
  Personalized vaccines and engineered cell therapies require expensive sequencing, manufacturing, and computational resources.
• Regulation and interpretability
  Regulatory agencies are still evolving frameworks for AI‑driven decision support and for therapies whose design pipeline is heavily AI‑mediated.
• Access and equity
  High‑resource academic centers are often first adopters; translating these methods to community oncology practices and lower‑income regions is an open challenge.

For researchers, clinicians, and strategists thinking about boosting the human immune system against cancer with AI:

1. Prioritize AI‑enabled personalization where possible
   • Consider enrolling eligible patients in trials of AI‑designed neoantigen vaccines plus checkpoint blockade, especially in melanoma and potentially lung and pancreatic cancers [1–4].
2. Use AI‑based prediction tools to guide immunotherapy
   • Incorporate validated AI models for predicting checkpoint inhibitor response and immune‑related toxicity in NSCLC and other cancers as they become clinically available [12–14].
3. Engage in multidisciplinary teams
   • Combine oncologists, immunologists, data scientists, and computational biologists to co‑develop and interpret AI systems, avoiding blind reliance on models.
4. Focus on interpretable, clinically integrated AI
   • Favor models that provide insight into why a given therapy is recommended (e.g., specific immune and tumor features) to improve trust and refine biological understanding.
5. Invest in longitudinal immune monitoring
   • Use AI to analyze serial pathology, imaging, and blood data to detect early resistance or toxicity and to adapt treatment plans appropriately.
6. Promote equitable data collection
   • Ensure that clinical data used to train AI models is diverse across ethnicity, geography, and cancer types to avoid widening disparities in immunotherapy outcomes.

Research over the last few years has made it increasingly clear that AI is becoming a central enabler of next‑generation cancer immunotherapy. Its key contributions are:

• Designing more precise, personalized immune attacks (vaccines, CAR‑T/NK, TILs).
• Identifying optimal drug combinations and schedules that transform tumors into immune‑responsive states.
• Predicting who will benefit and who is at risk of serious toxicity.
• Discovering new immune targets and mechanisms that can be therapeutically exploited.

These advances do not replace the human immune system; rather, they re‑engineer and guide it, making it far more effective at recognizing and destroying cancer while preserving healthy tissues. Over the coming decade, widespread integration of AI into immunotherapy research and clinical practice is likely to be one of the most important drivers in moving many cancers from lethal diseases to controllable or even curable conditions.